Relapsing Multiple Sclerosis Clinical Trials

14 recruiting

Frequently Asked Questions

Common questions about Relapsing Multiple Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 4

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Relapsing Multiple SclerosisPrimary Progressive Multiple Sclerosis
Hoffmann-La Roche60 enrolled17 locationsNCT07483450
Recruiting

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Multiple SclerosisPrimary Progressive Multiple SclerosisRemitting-Relapsing Multiple Sclerosis+3 more
Heinrich-Heine University, Duesseldorf837 enrolled2 locationsNCT07426991
Recruiting

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals800 enrolled111 locationsNCT05344469
Recruiting
Phase 2

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
Hoffmann-La Roche12 enrolled17 locationsNCT07161258
Recruiting
Phase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis
Sandoz175 enrolled40 locationsNCT06847724
Recruiting

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Relapsing Multiple Sclerosis
TG Therapeutics, Inc.16 enrolled4 locationsNCT06143514
Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.500 enrolled80 locationsNCT06433752
Recruiting
Phase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting
Phase 3

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
TG Therapeutics, Inc.360 enrolled42 locationsNCT07211633
Recruiting
Phase 1Phase 2

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled17 locationsNCT06617793
Recruiting
Phase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled86 locationsNCT06846281
Recruiting
Phase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals160 enrolled14 locationsNCT06486779
Recruiting
Phase 4

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Relapsing Multiple Sclerosis
University of Colorado, Denver100 enrolled3 locationsNCT06529406
Recruiting

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals174 enrolled10 locationsNCT05809986
Recruiting

Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
Neuromed IRCCS150 enrolled1 locationNCT04121065